TRADELABOR has more than 20 years of experience in the control and treatment of air, working with an experienced and qualified technical staff and with the most advanced technology in this area, which together guarantee the quality of the services provided.
This guidance is for immediate implementation
This guidance recommends steps manufacturers of APIs and drug products should take to detect
and prevent unacceptable levels of nitrosamine2 impurities in pharmaceutical products.3 The
guidance also describes conditions that may introduce nitrosamine impurities. The recent
unexpected finding of nitrosamine impurities, which are probable human carcinogens, in drugs
such as angiotensin II receptor blockers (ARBs), 4 ranitidine, 5 nizatidine, 6 and metformin,
7 has made clear the need for a risk assessment strategy for potential nitrosamines in any pharmaceutical product at risk for their presence.
Continue at: https://www.fda.gov/media/141720/download
The text above is owned by the site above referred.
Here is only a small part of the article, for more please follow the link